Mazdutide是一种有长效作用的胰高血糖素样肽-1受体（GLP-1R；Ki=28.6nM）和胰高血糖素受体（GCGR；Ki=17.7nM）双重激动剂。
Cas No.:2259884-03-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Mazdutide is a long-acting dual agonist of the glucagon-like peptide-1 receptor (GLP-1R; Ki=28.6nM) and the glucagon receptor (GCGR; Ki=17.7nM)[1-2]. Mazdutide can suppress appetite and slow gastric emptying by activating the GLP-1 receptor to reduce energy intake, while simultaneously increasing energy expenditure and promoting hepatic fat breakdown by activating the GCG receptor to improve metabolism. Mazdutide is used for the long-term management of adult overweight/obesity and the treatment of type 2 diabetes[3-4].
In vivo, db/db mice were subcutaneously administered Mazdutide (50-200μg/kg) once every three days for 12 consecutive weeks. Mazdutide significantly improved diabetes-associated cognitive dysfunction[5]. C57BL/6J male mice with obesity induced by a 13-week high-fat diet were subcutaneously administered Mazdutide (15nmol/kg) once every three days for 4 weeks. Mazdutide significantly reduced hepatic fat accumulation, and its effect was superior to that of a GLP-1R mono-agonist[6].
References:
[1] Shirley M. Mazdutide: First Approval. Drugs. 2025 Dec;85(12):1621-1627.
[2] Pan XF, Fang ZZ, Zhang L, et al. Obesity in China: current progress and future prospects. Lancet Diabetes Endocrinol. 2026 Feb;14(2):178-186.
[3] Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025 May;187:171380.
[4] Sidrak WR, Kalra S, Kalhan A. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. Indian J Endocrinol Metab. 2024 Sep-Oct;28(5):445-460.
[5] Dong W, Bai J, Yuan Q, Z, et al. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis. EBioMedicine. 2025 Jul;117:105791.
[6] Xia H, Min Y, Wang Y, et al. Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model. Radiology. 2025 Aug;316(2):e243780.
Mazdutide是一种有长效作用的胰高血糖素样肽-1受体（GLP-1R；Ki=28.6nM）和胰高血糖素受体（GCGR；Ki=17.7nM）双重激动剂[1-2]。Mazdutide可通过激活GLP-1受体抑制食欲、延缓胃排空以减少能量摄入，同时通过激活GCG受体增加能量消耗、促进肝脏脂肪分解以改善代谢。Mazdutide可用于成人超重/肥胖的长期体重管理和2型糖尿病的治疗[3-4]。
在体内，Mazdutide（50-200μg/kg）每三天一次皮下注射，用于处理的db/db小鼠，连续12周。Mazdutide显著改善了糖尿病相关的认知功能障碍[5]。Mazdutide（15nmol/kg）每三天一次皮下注射，用于处理经13周高脂饮食诱导的C57BL/6J雄性肥胖小鼠，持续4周。Mazdutide显著减少了肝脏脂肪积累，且效果优于GLP-1R单激动剂[6]。
| Animal experiment [1]: | |
Animal models | db/db mice |
Preparation Method | Male db/db mice were subcutaneously administered three escalating doses of Mazdutide (50, 100, 200μg/kg) or dulaglutide (200μg/kg) once every three days for 12 weeks. Cognitive function, metabolic parameters, brain pathology, and molecular pathways were evaluated at the end of treatment. |
Dosage form | 50, 100, 200μg/kg; s.c.; Once every three days for 12 weeks. |
Applications | Mazdutide administration led to significant body weight loss, improved glycemic control, and ameliorated diabetes-associated cognitive dysfunction. Mazdutide improved performance in behavioral tests, reduced neuronal injury and myelin decline in the hippocampus, and modulated pathways related to neurotransmission, neuroinflammation, and synaptic plasticity. |
References: | |
| Cas No. | 2259884-03-0 | SDF | Download SDF |
| 别名 | IBI-362; LY-3305677; OXM-3 | ||
| 分子式 | 分子量 | 4563.06 | |
| 溶解度 | H2O : 22.22 mg/mL (ultrasonic and adjust pH to 2 with HCl) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 219.2 μL | 1.0958 mL | 2.1915 mL |
| 5 mM | 43.8 μL | 219.2 μL | 438.3 μL |
| 10 mM | 21.9 μL | 109.6 μL | 219.2 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet